Can you take Isavuconazonium with Satralizumab?
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- isavuconazonium
- satralizumab
Drug interactions
Moderate drug interactions
Moderate:
isavuconazonium satralizumab
Applies to: isavuconazonium and satralizumab
Satralizumab may alter the blood levels and effects of isavuconazonium.
Your doctor may need to monitor you more closely and/or adjust the dosing of your medication(s).
For example, a dose adjustment may be needed if you have been receiving isavuconazonium and are starting treatment with satralizumab. Likewise, if you have been receiving both medications, the dose of isavuconazonium may need to be adjusted when satralizumab is discontinued.
Contact your doctor if your condition changes or you experience increased side effects.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Liver Disease, Infection, Tuberculosis, Active, Tuberculosis, Latent, and Infectious Hepatitis.
Infection
Moderate:
satralizumab
Satralizumab has a moderate potential interaction with Infection.
Treatment with satralizumab can increase the risk of serious infections. Treatment should be delayed until any active infection is treated and resolved.
Infectious Hepatitis
Major:
satralizumab
Satralizumab has a major potential interaction with Infectious Hepatitis.
Satralizumab is contraindicated in patients with active hepatitis B infection. All patients should be screened for hepatitis B before treatment initiation.
Liver Disease
Moderate:
isavuconazonium
Isavuconazonium has a moderate potential interaction with Liver Disease.
The use of isavuconazonium has been associated with hepatic adverse reactions (e.g., elevations in ALT, AST, alkaline phosphatase, total bilirubin). Cases of more severe hepatic reactions (including hepatitis, cholestasis, hepatic failure including death) have been reported during therapy in patients with serious underlying medical conditions (e.g., hematologic malignancy). Liver-related laboratory tests should be evaluated at the start and during therapy. Isavuconazonium has not been studied in patients with severe liver dysfunction (Child-Pugh C) and should be used in these patients only when the benefits outweigh the risk. Clinical monitoring for drug-related side effects is recommended when treating patients with severe liver dysfunction.
Short QT Syndrome
Major:
isavuconazonium
Isavuconazonium has a major potential interaction with Short QT Syndrome.
Isavuconazonium shortened the QTc interval in a concentration-related manner. This drug is contraindicated in patients with familial short QT syndrome.
Tuberculosis, Active
Major:
satralizumab
Satralizumab has a major potential interaction with Tuberculosis, Active.
Satralizumab is contraindicated in patients with active or untreated latent tuberculosis. All patients should be screened for tuberculosis before treatment initiation and monitored for the development of symptoms or signs of tuberculosis during treatment, even if the initial testing is negative.
Tuberculosis, Latent
Major:
satralizumab
Satralizumab has a major potential interaction with Tuberculosis, Latent.
Satralizumab is contraindicated in patients with active or untreated latent tuberculosis. All patients should be screened for tuberculosis before treatment initiation and monitored for the development of symptoms or signs of tuberculosis during treatment, even if the initial testing is negative.
Report options
More resources
isavuconazonium
A total of 527 drugs are known to interact with isavuconazonium.
- Isavuconazonium is in the drug class azole antifungals.
- Isavuconazonium is used to treat the following conditions:
satralizumab
A total of 372 drugs are known to interact with satralizumab.
- Satralizumab is in the drug class interleukin inhibitors.
- Satralizumab is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.